Lung disease

#Antibody-based therapeutics #Fibrosis #Lung disease #Mediar Therapeutics #Phase I trial

Phase I IgG1 antibody treatment could halt fibrosis

The first cohort of participants has been dosed in a Phase I trial MTX-474, a human IgG1 antibody designed to neutralise EphrinB2 signalling to treat fibrosis. The study, taking place in Australia, is designed to assess the safety, tolerability, pharmacokinetics, and target engagement of MTX-474 in… Read More

#News

Lungs
#Autoimmune disease #Clinical trial #GSK #Interview #Lung disease

GSK’s autoimmune efforts

DDW Editor Reece Armstrong speaks to Roger Levy, Global Medical Expert Immunology & Specialty Medicine at GSK about the company’s work into treating systemic sclerosis-associated interstitial lung disease and its recent BLISSc-ILD study evaluating its belimumab treatment.  RA: Can you give us an overview of the BLISSc-ILD study? RL: The BLISSc-ILD study… Read More

#Exclusive Content

Respiratory system
#AI #Anima Biotech #Idiopathic pulmonary fibrosis #Lung disease #mRNA #Preclinical investigations

AI mRNA candidate shows early promise in lung fibrosis

A therapeutic candidate which operates through a novel mRNA biology mechanism of action could open new avenues for treating idiopathic pulmonary fibrosis (IPF) patients. Anima Biotech has identified a preclinical candidate, effectively disrupting the transformation of fibroblasts into fully differentiated myofibroblasts. By inhibiting myofibroblasts’… Read More

#News

Qureight platform image
#AI / data analytics / healthtech / informatics #AstraZeneca #Lung disease #Qureight

Qureight and AZ collaborate on lung disease research

Cambridge data analytics company Qureight has announced a multi-year strategic research collaboration with AstraZeneca. The agreement will allow AstraZeneca to use Qureight’s proprietary platform and artificial intelligence (AI) technology to conduct research across a range of complex lung diseases. It is hoped that this will help… Read More

#News

Clinical trial
#Bellerophon Therapeutics #Lung disease #Phase III trial #Pulmo

Phase III pulmonary fibrosis drug trial fails

Bellerophon Therapeutics has announced it will close its Phase III study of INOpulse, its treatment for fibrotic Interstitial Lung Disease (fILD), after the trail failed to meet its primary endpoint. The REBUILD clinical trial was designed as a randomised, double-blind, placebo-controlled Phase III study evaluating the… Read More

#News

Respiratory system
#AnaMar #Clinical trial #Fibrosis #Lung disease #Phase I trial

Positive Phase I data for oral fibrosis treatment

AnaMar has announced positive results from its Phase I study, and the completion of Phase II enabling pre-clinical studies, for AM1476’s initial orphan indication in systemic sclerosis (SSc) characterised by lung and skin fibrosis. AM1476, a highly selective small molecule, delivered as an orally administered tablet,… Read More

#News

Lungs
#Idiopathic pulmonary fibrosis #Lung disease #Phase II trial #Vicore Pharma

New drug shows sustained disease stabilisation in IPF

New Phase IIa data indicates that Vicore Pharma’s C21 has the potential to transform the treatment of idiopathic pulmonary fibrosis (IPF) and restore lung function. In data from the AIR trial, C21 has demonstrated long-term efficacy. At 36 weeks, the average forced vital capacity (FVC) had… Read More

#News

Pseudomonas aeruginosa bacteria
#Bacteria #Clinical trial #Infex Therapeutics #Lung disease #Phase I trial

Encouraging results for RESP-X in ongoing Phase I clinical trial

RESP-X, Infex Therapeutics’ anti-virulence therapy to treat Pseudomonas aeruginosa (Pa) infections in non-cystic fibrosis bronchiectasis (NCFB) patients, has shown a promising interim safety and tolerability profile in its ongoing first-in-human Phase I clinical trial. The first cohort consisted of eight healthy volunteers who received doses of… Read More

#News

Woman doing clinical research
#Computational chemistry #Drug discovery #Drug repurposing #Idiopathic pulmonary fibrosis #Lung disease #Medicines repurposing #Preclinical investigations

Cancer drug shows promise in treating incurable lung disease 

Researchers have shown that the medication saracatinib shows promise as a treatment for idiopathic pulmonary fibrosis (IPF).   Saracatinib worked as well or better than two approved drugs at reducing tissue scarring in preclinical models of IPF according to the study published in the American Journal of… Read More

#News

Chest CT images
#AI #Artificial intelligence (AI) #Idiopathic pulmonary fibrosis #Imaging #Lung disease

Phase II IPF trial to benefit from AI imaging

Brainomix has partnered with Bridge Biotherapeutics to deliver AI imaging biomarker analysis within the Phase II study of novel autotaxin inhibitor BBT-877 in idiopathic pulmonary fibrosis (IPF). Under the partnership, Brainomix will leverage its e-ILD technology (automated artificial intelligence software) which has been trained to process high resolution chest CT… Read More

#News

Lungs
#Lung disease #Novel therapeutics

Webinar on novel approaches to human lung disease modelling

DDW was delighted to work with CN Bio on an exclusive event which focused on novel approaches to human lung disease modelling.  The free event took place on 29 March at 3pm.  It covered:  Accelerating the discovery of new therapeutics for treatment… Read More

#News